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ABSTRACT
Comparison of Testosterone Replacement Therapy
Medications in the Treatment of Hypogonadism
Christopher M. Williams
College of Nursing, BYU
Master of Science
Hypogonadism is one of the most common endocrinologic syndromes seen in
clinical practice. Testosterone replacement therapy (TRT) is one possible treatment
option for men with hypogonadism. When TRT is a viable treatment option, routes of
administration, effectiveness, patient compliance, cost, and potential side effects should
be carefully considered by the Nurse Practitioner. In the United States TRT is available
via intramuscular, nasal, buccal, and topical routes. All transdermal testosterone is the
most effective when regulating testosterone levels. Depotestosterone, an injectable form
of testosterone, promotes patient compliance, is considered safe, and is affordable. Nurse
Practitioners should initiate TRT with Depotestosterone.
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Medications in the Treatment of Hypogonadism
Hypogonadism, a disease process whereby the body is unable to produce

sufficient amounts of testosterone (Bhasin et al., 2010), is one of the most common
endocrinologic syndromes seen in clinical practice (Darby & Anawalt, 2012). In males,
testosterone levels normally peak in adolescence and/or early adulthood, but then
gradually decline by approximately 1% per year (Mayo Foundation for Medical
Education and Research, 2015). Nearly 40% of men over the age of 45 years have agerelated or late-onset hypogonadism, defined as testosterone at or below 200 ng/dL
(Cleveland Clinic Foundation, 2015; Urology Care Foundation, 2015).
Low testosterone levels not only cause concerning symptoms but may also have
serious complications. Symptoms are varied and may include decreased libido, erectile
dysfunction, low energy, trouble concentrating, reduced muscle mass, decreased bone
density, increased body fat, and/or depression (Dandona & Rosenberg, 2010; Pantalone
& Faiman, 2012). If untreated, low testosterone levels may lead to issues with decreased
red blood cell production, bone fractures, central obesity, muscle wasting,
depression/suicidal ideation, and decreased cognitive function (President and Fellows of
Harvard College, 2013).
The number of testosterone prescriptions in the United States (US) has increased
three fold since 2001 (Baillargeon, Urban, Ottenbacher, Pierson, & Goodwin, 2013). This
may be due to publicity about the symptoms of hypogonadism making the condition
more recognizable to patients and healthcare providers (Allan, Strauss, Forbes, Paul, &
McLachlan, 2011). Because the overall US population is aging (Ortman, Valkoff, Hogan,
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2014) and late-onset hypogonadism is associated with aging, it is likely that the use of
testosterone will continue to increase. It is prudent, therefore, for Nurse Practitioners
(NPs) to familiarize themselves with the diagnosis, treatment, and management of
hypogonadism in the clinical setting (Lee, 2013).
Testosterone replacement therapy (TRT) is one possible treatment option for men
with hypogonadism, a condition commonly referred to as Low-T, and also may be
beneficial for older men in whom testosterone levels are suboptimal (Osterberg, Bernie,
& Ramasamy, 2014). TRT has been shown to produce a significant improvement in
quality of life (Bhattacharya & Bhattacharya, 2015) and has an important role in
maintaining cardiovascular health (Oskui, French, Herring, Mayeda, Burstein, & Kloner,
2013). In addition, when hypogonadal men are treated with TRT, obesity, type 2 diabetes
mellitus, and exercise capacity improve (Oskui et al., 2013). Furthermore, the 2010
Endocrine Society clinical practice guidelines for men with clearly documented androgen
deficiency recommended “testosterone therapy for symptomatic men with classical
androgen deficiency syndromes aimed at inducing and maintaining secondary sex
characteristics and at improving their sexual function, sense of well-being, and bone
mineral density” (Bhasin et al., 2011, p. 2537).
However, TRT may not be an appropriate treatment option for some male
patients. Generally speaking, TRT is contraindicated for men with breast or prostate
cancer, a prostate nodule or induration, or a Prostate Specific Antigen (PSA) above 4
ng/ml or above 3 ng/ml in male patients at high risk for prostate cancer. TRT is also
contraindicated in men who have a hematocrit higher than 50%, severe obstructive and	
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untreated sleep apnea, severe urinary tract symptoms, or heart failure (Bhasin et al.,
2011).
When TRT is a viable treatment option, routes of administration, effectiveness,
cost, and potential side effects should be considered. For instance, in the US TRT is
available via intramuscular, nasal, buccal, and topical routes. Therefore, the purpose of
this article is to review various forms of TRT comparing their effectiveness, likelihood of
promoting patient compliance, cost, and potential side effects.
Methods
	
  
Six electronic databases were searched to identify studies and literature reviews
relating to TRT efficacy, side effects, and cost. The databases included CINAHL,
MEDLINE, Pubmed, Cochrane Library, Health Source: Nursing/Academic Edition, and
Web of Science. In addition, reference sources such as UpToDate and Epocrates were
reviewed. Many websites were also reviewed, including the Mayo Clinic, Cleveland
Clinic, Urology Care Foundation, American Association of Clinical Endocrinologists,
Agency for Healthcare Research and Quality, GoodRx, US Food and Drug
Administration (FDA), drugs.com, medicinenet.com, the Endocrine Society, and
manufacturers of TRT medications currently approved for use in the US.
Inclusion criteria included: research published from 2011-2016 initially, but was
expanded to include research published from 1997 to 2016 in English; research focused
on treatment of hypogonadism in immunocompetent adult men; prescription medications;
and, FDA approved medications for use in the US. Because efficacy and side effects were
unavailable for some TRT medications in the literature, we included data from the
package inserts of some medications as published either on the FDA website or the
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manufacturer website. Exclusion criteria included: compounded or combination TRT
medications; and, studies including subjects with other co-morbidities. Search terms
included: hypogonadism, testosterone, testosterone replacement therapy, efficacy, cost,
price, and Low-T.
	
  

Results
Ten studies met the inclusion criteria: five studies independently evaluated the

efficacy and side-effects of a single TRT medication (Arver et al., 1997; Mattern,
Hoffmann, Morley, & Badiu, 2008; Ross et al., 2004; Wang, Cunningham, et al., 2004;
Wang, Swerdloff, et al., 2004) and five studies compared the efficacy and side effects of
two or more TRT medications (Dobs Matsumoto, Wang, & Kipnes, 2004; Grober, Khera,
Soni, Espinoza, & Lipshultz, 2008; Korbonits et al., 2004; Mazer et al., 2005; Steidle et
al., 2003). The product monograph or package insert was also evaluated for all 14
prescription TRT medications for all delivery routes and strengths as published on the
USFDA website and/or product manufacturer websites.
Testosterone Replacement Therapy Precautions
	
  
NPs should be aware that all TRT medications have potential side effects and
should be carefully considered before initiating TRT. All of these medications can
potentiate electrolyte imbalances, resulting in retention of nitrogen, sodium, potassium,
and phosphorus. Additionally, TRT medications can cause decreased urinary excretion of
calcium resulting in hypercalcemia (Pfizer Canada Inc., 2015).
Adverse effects can occur with any TRT medication. Some of these adverse
events are clearly linked to TRT whereas others are uncommon and less clearly linked.
Adverse effects that are clearly related to TRT include: 1) erythrocytosis; 2) urinary
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retention; 3) acne; and 4) reduced sperm production (Bebb, 2011; Hassan & Barkin,
2016). Side effects that are less common, or not clearly linked to TRT, include: 1)
gynecomastia; 2) adrenergic alopecia; 3) worsening benign prostatic hyperplasia; 4)
obstructive sleep apnea (OSA) or worsening of already existing OSA; 5) fluid retention;
6) growth of an already existing prostate cancer; and 7) breast cancer (Bebb, 2011;
Hassan & Barkin, 2016).
All prescription TRT medications, regardless of formula, are Schedule III
controlled substances, meaning that the medications have the potential for abuse and can
lead to low to moderate physical dependence or high psychological dependence (Drug
Enforcement Agency, 2016). Therefore, an increase in testosterone prescriptions comes
with an increased risk for abuse. Historically, testosterone misuse was found only among
elite athletes, however TRT abuse is now documented among men who want to enhance
their physical appearance and is commonly found among bodybuilders and weightlifters
(American Society of Health-System Pharmacists, 2015).
Injectable Testosterone
	
  
Currently in the United States, there are three types of injected testosterone
approved for TRT in hypogonadal men: Depotestosterone (testosterone cypionate),
Delatestryl (testosterone enanthate), and Aveed (testosterone undecanoate). The side
effects and potential adverse effects of all testosterone injection medications are similar
to those for all TRT preparations with the addition of injection site pain although the pain
is short-lived.
Depotestosterone (testosterone cypionate). According to GoodRx.com (2016),
Depotestosterone is the most popularly prescribed TRT medication in the US. It is a long-
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acting testosterone and only needs to be administered approximately once every 2-weeks.
The most common dose is 200 milligrams (mg) in 1 milliliter (ml) (Snyder, 2016). The
generic form is available in two doses: 100 mg/ml and 200 mg/ml. The 100 mg/ml is
available in a 10 ml vial, while the 200 mg/ml is available in 10 ml vial or 1 ml vial.
When calculated from the most commonly prescribed dose, the average cost per month is
$22.70 for the 100 mg/ml (10 ml vial) and $18.45 for the 200 mg/ml (10 ml vial)
(Epocrates, 2016). The 200 mg/ml in the 1 ml vial is considerably more expensive at
$98.07/month (See Table 1).
Depotestosterone is commonly prescribed in the US and has been used safely for
decades, however the literature does not address its effectiveness and side-effects. The
benefit of Depotestosterone is the twice monthly dosing, however, the disadvantage of
intramuscular administration may negatively affect patient compliance (Snyder, 2016).
When administered, testosterone levels quickly increase and then gradually decrease until
the next injection. Thus, there may be fluctuations in testosterone levels. This variability
can be minimized by shortening the amount of time between injections (i.e. 100 mg/week
rather than 200 mg/every other week) (Snyder, 2016).
Delatestryl (testosterone enanthate). Similar to Depotestosterone, Delatestryl is a
long-lasting testosterone IM injection that only needs to be administered approximately
every 2-weeks. Delatestryl has also been used for TRT for decades and is available at 200
mg/ml in a 5 ml vial. The most commonly prescribed dose is 1 ml every 2-weeks.
Deletestryl is also available as a generic preparation and costs, on average, $23.46/month
(Epocrates, 2016) (See Table 1).

6	
  

Generally, Delatestryl is well tolerated by patients. Adverse reactions are very
rarely reported but include the potential for anaphylaxis. Thus, patients should be
observed immediately following the injection for any signs of anaphylaxis, including
cough and respiratory distress. Benefits of Delatestryl for TRT include twice/month
dosing. IM injection, however, may affect patient compliance (Food and Drug
Administration [FDA], 2016). Since 2014, Deletestryl has been in short supply and may
be difficult to obtain.
Aveed (testosterone undecanoate). Aveed is a very-long acting TRT medication
that requires a 3 ml IM injection approximately once every 10-weeks to maintain normal
testosterone levels. According to data from the manufacturer, testosterone peaks about 1week following injection and gradually decreases until the next injection (FDA, 2016).
Currently, Aveed has no generic substitute and is available in one dose: 750 mg/3 ml in a
3 ml vial. Because Aveed is only available as a brand name, the cost is considerably
higher than other injectable TRT medications at $949.02 per vial or an average monthly
cost of $379.60 (Drugs.com, 2016).
Because Aveed is associated with pulmonary oil microembolism (POME) and
anaphylaxis, though only rarely, the US has restricted its availability as part of the Aveed
Risk Evaluation and Mitigation Strategy or REMS program. In 18 clinical trials with a
total of 3,556 subjects, a total of 9 POME and 2 anaphylaxis events occurred. As part of
the REMS program, Aveed can only be administered in a clinic or hospital setting and the
patient must be observed for 30 minutes following injection. Other less serious side
effects occur in <5% of patients, the most common of which is acne and injection site
pain (FDA, 2016).
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Nasal Testosterone
	
  
Natesto is a testosterone-based nasal gel the patient self-administers three times
per day. Approximately 40 minutes after administration, testosterone levels return to
within normal limits, although Natesto’s half-life is widely variable, between 10 and 100
minutes (Mattern et al., 2008). Each bottle of Natesto delivers approximately 60
actuations but, when taken as commonly prescribed, 180 actuations constitute a 1-month
supply, therefore, three bottles are needed each month. Natesto is not available in generic
form and costs $233.07 per bottle or $699.21 per month (GoodRx.com, 2016) (See Table
1).
According to the manufacturer, side effects occurred in <9% of patients during
the 180-day clinical trial and most commonly included nasopharyngitis, rhinorrhea,
parosmia, headache and nasal discomfort and scabbing (FDA, 2016). Benefits of Natesto,
when compared to other TRT medications, include a less invasive delivery method and
less risk of inadvertently transferring the gel to a partner or child (Snyder, 2016). In
contrast, one notable disadvantage of Natesto is the three times per day dosing schedule,
which may be inconvenient for some patients (Snyder, 2016). Because of its unique
method of delivery, Natesto is not recommended for patients with chronic nasal or sinus
conditions or allergic rhinitis (FDA, 2016).
Buccal Testosterone
	
  
Striant is the only available buccal form of testosterone. It is available in a 30 mg
tablet and is commonly prescribed twice per day (Epocrates, 2016). Manufacturer data
from one 12-week clinical study showed Striant provided steady testosterone levels for
86.6% of subjects (FDA, 2016). The most common side effect in long-term extension
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trials was gingivitis (32.6%). Other side effects occurred in <10% of subjects but
included gum irritation/pain/edema, bitter taste, and headache (FDA, 2016). Because no
generic is available, the average cost for a 1-month supply of Striant is $724.77
(Epocrates, 2016) (See Table 1). Advantages to buccal testosterone include quick
delivery of medication using a less invasive method which may increase compliance. The
fact that the tablet never completely dissolves and needs to be removed before placing
another one, as well as the need to recheck placement after brushing teeth, eating, or
drinking are disadvantages.
Two head-to-head comparison studies have been published on Striant (Dobs et al.,
2004; Korbonits et al., 2004) one of which compared Striant to the Androderm patch
(Korbonits et al., 2004) and the second of which compared Striant to Androgel 1%
packets. The mean total testosterone level was similar between Striant and Androgel
(Dobs et al., 2004). However, Korbonits et al. (2004) concluded that Striant was superior
to the Androderm patch because Striant subjects’ testosterone levels were always within
normal limits over a 24 hour period whereas Androderm subjects fell below the normal
testosterone range during the first 2 hours of placing the patch.
Two additional studies, independent of the manufacturer, have been conducted
with Striant (Ross et al., 2004; Wang, Swerdloff, et al., 2004). In both studies, Striant was
found to effectively elevate serum testosterone levels within 24 hours of initiating
treatment (Ross et al., 2004; Wang, Swerdloff, et al., 2004). No side effects were reported
in one study (Ross et al., 2004); however, 16.3% of subjects in the Wang, Swerdloff, et
al. (2004) study reported gum-related irritation.

9	
  

Transdermal Testosterone
	
  
Several transdermal testosterone products are available by prescription in the US.
All deliver testosterone across the skin for systemic distribution and are available as a
patch or gel. Although all the gel formulas are applied to the skin in the same manner, the
medications are packaged as a pump, packet, or tube. Brand names for transdermal
testosterone include Androderm, Androgel, Axiron, Fortesta, and Vogelxo. One notable
advantage of transdermal delivery is that it has a continuous delivery of medication and is
easy to apply. Disadvantages include skin irritation, inadvertent contact transfer with
others, and some restrictions on activity such as bathing or swimming.
Androderm patch. The Androderm patch is available in two different strengths: 2
mg and 4 mg, although the 4 mg dose is the most commonly prescribed (Drugs.com,
2016). The patch should be applied to non-scrotal skin and then replaced every 24 hours,
rotating sites with each application. The per month cost of Androderm is $195.03 for 30
patches (Epocrates, 2016) (See Table 1). Manufacturer data show Androderm produces
normal testosterone levels in 92% of patients (FDA, 2016). The manufacturer also
compared Androderm to injected Deletestryl (testosterone enanthate) during a 6-month
trial, reporting normalized testosterone levels in 82% of Androderm subjects and 72% of
Deletestryl subjects (FDA, 2016). However, 37% of patients using Androderm had
pruritis at the application site and 12% had a burn-like blister that formed under the patch
(FDA, 2016).
One independent study evaluated the effectiveness and side effects of Androderm
(Arver et al., 1997). Arver et al. (1997) found Androderm to normalize testosterone levels
in subjects, as well as mimic the natural circadian pattern of testosterone during a day.
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However, Androderm also caused skin irritation in 56% of subjects and burn-like blisters
at the application site in 18% of subjects (Arver et al., 1997).
Korbonits et al. (2004) found that although Striant and Androderm both returned
testosterone levels to normal, Androderm subjects had greater variability in maintaining a
minimum testosterone level. This means that over a 24 hour treatment period, subjects
receiving Striant maintained normal testosterone levels whereas subjects receiving
Androderm had lower than normal testosterone levels for a short period of time, usually
within the first two hours of applying the patch (Korbonits et al., 2004). For this reason,
and the finding that there were very few subjects who suffered side effects in either
group, Korbonits et al. (2004) concluded that Striant was superior to Androderm.
In two additional studies, Androderm was compared to Testim (testosterone) 1%
gel tubes (Steidle et al., 2003) and Androgel (testosterone) 1% gel packets (Mazer et al.,
2005). Steidle et al. (2003) concluded that treatment with two Testim 1% gel tubes per
day (100 mg total) was superior to Androderm in normalizing testosterone levels. Mazer
et al. (2005) reported similar efficacy and localized skin-related side effects between
Androderm and Androgel 1% packets. Testim 1% gel tubes (100 mg) caused a
statistically significant increase in hematocrit and hemoglobin when compared to
Androderm. Furthermore, dermal-related side effects, such as erythema, rash, pruritis,
and irritation occurred much more frequently in the Androderm group (Steidle et al.,
2003).
Gel pumps/packets/tubes. Transdermal testosterone gel is packaged as either a
pump, a packet, or a tube. When prescribed as a pump, the most common dosing
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schedule is 2-4 pumps each day. Packets and tubes are both designed for single use,
meaning a 1-month supply would take 30 packets or 30 tubes.
Androgel (testosterone gel) is available in a pump and packet form at 1% or
1.62% doses. Similarly, Fortesta (testosterone gel) 2% and Axiron 2% gel are available as
a pump, but Axiron does not currently have a generic equivalent. Vogelxo (testosterone
gel) 1% is available as a pump, a packet, and a tube. Testim (testosterone gel) 1% is only
available in tubes. All transdermal gel formulations require patients to wash their hands
with soap and water after application and apply clothing only after the gel has dried.
Additionally, transdermal gel formulations carry the risk of unintentionally transferring
medication to a partner or children. With the use of any transdermal gel, NPs should
instruct patients to avoid site application contact with children and women until the area
has been either washed or clothed.
Average cost for a 1-month supply of testosterone gel pumps/packets/tubes varies.
The most expensive testosterone gel is Axiron 2% pump at $630.78 (Epocrates, 2016).
The next most expensive testosterone gel is Androgel (testosterone gel) costing $516.41
for the 1.62% packets and $510.77 for the 1.62% pump (GoodRx.com, 2016). All
remaining formulas are similar in price for a 1-month supply: Androgel 1% pump for
$309.24; Androgel 1% packets for $309.25; Vogelxo 1% pump for $283.69; Fortesta 2%
pump for $281.80; Vogelxo 1% packets for $270.30; Testim 1% tubes and Vogelxo 1%
tubes are the same price at $268.25 (GoodRx.com, 2016) (See Table 1).
Four studies compared the efficacy and side effects of testosterone gel in packets
and tubes to other testosterone medications (Dobs et al., 2004; Grober et al., 2008; Mazer
et al., 2005; Steidle et al., 2003). Striant and Androderm were found to have similar
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efficacy and occurrence of side effects when compared to Androgel 1% packets (Dobs et
al., 2004; Mazer et al., 2005). When comparing Testim 1% gel tubes to Androderm,
Steidle et al. (2003) concluded Testim 1% gel tubes were superior at achieving normal
testosterone levels and that Androderm generally had a higher incidence of side effects.
However, Testim 1% gel tubes had one statistically significant side effect when
compared to Androderm, that of increased hematocrit and hemoglobin (Steidle et al.,
2003).
Grober et al. (2008) compared efficacy and side effects between two testosterone
gel packets in hypogonadal men who had suboptimal testosterone levels despite treatment
with either Androgel or Testim. In the crossover study, researchers concluded that when
subjects switched from Androgel to Testim, they had a more favorable response with
stable testosterone levels. In the same study, researchers reported that when subjects were
changed from Testim to Androgel, there were fewer side effects.
Wang, Cunningham, et al. (2004) compared the efficacy of Androgel 1% packets
in varying doses (ie 1 packet daily or 2 packets daily). During the course of the study, the
Androgel 1% packets could be titrated to achieve optimal testosterone levels in subjects
(Wang, Cunningham, et al., 2004). The researchers reported that when titrated, Androgel
1% packets resulted in patient outcomes similar to injectable testosterone or other
transdermal formulas (Wang, Cunningham, et al., 2004). Additionally, Androgel 1% gel
packets did not cause skin irritation and were found to be safe and effective, even in longterm treatment.
Manufacturer data regarding efficacy, as reported in package inserts, were also
reviewed. After the subjects’ dose was titrated appropriately, Axiron 2% was the most
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effective resulting in normal testosterone levels in 89% of subjects. Effectiveness of
Androgel 1% and 1.62% was reported as 87% and 81.6% after titration, respectively.
Fortesta 2% was efficacious in 77.5% of subjects after titration and Testim 1% resulted in
normal testosterone levels in 74% of subjects after titration (FDA, 2016).
Package insert information regarding side effects of Testim 1%, Vogelxo 1%,
Axiron 2%, Fortesta 2%, and Androgel 1% and 1.62% were also reviewed. Testim 1%
and Vogelxo 1% reported the least occurrence of side effects, both reported in less than
5% of subjects. The most common side effect reported in Testim 1% and Vogelxo 1%
was skin irritation at the application site. With Axiron 2% and Androgel 1% and 1.62%
side effects were found in less than 10% of subjects. The most common side effect of
Axiron 2% was skin irritation at the application site. Acne was the most common side
effect of Androgel 1% and 1.62%. Finally, Fortesta 2% had the highest occurrence of
side effects at 17% of subjects, the most common of which was skin irritation at the
application site (FDA, 2016).
	
  

Discussion
In 2010, the Endocrine Society published TRT clinical practice guidelines.

According to the updated guidelines, healthcare providers should recommend TRT for
symptomatic men with unequivocally low serum testosterone levels that was collected
from a morning serum sample. All TRT should have clear treatment goals that are aimed
at maintaining secondary sex characteristics and improving sexual function, sense of
well-being, and bone mineral density (Bhasin et al., 2010).
The Endocrine Society also published guidelines on contraindications for TRT
and routine TRT follow-up appointments. Risk of prostate or breast cancer, hematocrit
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above 50%, untreated and severe obstructive sleep apnea, severe lower urinary tract
symptoms, uncontrolled or poorly controlled heart failure, and desire of fertility are all
contraindications for TRT (Bhasin et al., 2010). All patients undergoing TRT should be
evaluated 3-6 months after initiation and then annually, aiming for testosterone levels in
the mid-normal range (Bhasin et al., 2010).
The efficacy of TRT preparations should be considered when selecting a TRT
medication. We confirmed that TRT medications administered every day, rather than
every few weeks, most consistently maintained testosterone levels within a normal range.
Since all transdermal TRT medications are prescribed on a once per day dosing schedule,
it would appear that transdermal TRT preparations, in general, are more efficacious than
TRT medications with more frequent or less frequent dosing schedules.
Compliance is another consideration when prescribing TRT for patients since the
number of medication doses each day can have a significant effect on patient compliance.
Indeed, there is an inverse relationship between the number of medication doses and
patient compliance: the higher the number of medication doses in a day, the lower the
patient compliance (Claxton, Cramer, & Pierce, 2001). Some testosterone medications,
such as Natesto and Striant, are prescribed three times per day or two times per day,
respectively. As a result, the dosing schedule for Natesto and Striant could negatively
affect patient compliance. Using this same logic, however, it would seem that
Depotestosterone and Delatestryl would be associated with greater patient compliance
because these two injected testosterone medications only need to be administered every
2-weeks. Additionally, Aveed is only administered once every 10-weeks which would
seemingly improve patient compliance further.
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Cost should always be considered when prescribing any medication. A review of
all testosterone medications revealed that the most cost-efficient TRT medications were
injectable formulations, namely Depotestosterone and Delatestryl. Depotestosterone is
commonly prescribed at 200mg/ml every 2-weeks and is available for dispense in a 10ml
vial for $92.29 (Epocrates, 2016). The 10ml vial of Depotestosterone, however, would
have enough medication for 5-months, for an average monthly cost of $18.45. In
comparison, Delatestryl is commonly prescribed at 200mg/ml every 2-weeks and can be
dispensed in a 5ml vial for $23.46 (GoodRx.com, 2016). The 5ml vial of Delatestryl
would contain enough doses for 2.5-months for an average monthly cost of $23.46. When
compared to the cost of transdermal patches at $195.03 per month or the cost of nasal gel
at $699.21 per month, the cost difference is notable (See Table 1).
Finally, side effects of each TRT medication should be carefully evaluated. The
injectable testosterone Depotestosterone is not well studied, even though it has been
available the longest and is the most frequently prescribed of all types of TRT
medications with seemingly few side effects. Anaphylaxis is rarely seen as a side effect
of Delatestryl, another injectable testosterone. Aveed is a long-acting injectable
testosterone that is rarely associated with POME and anaphylaxis, although its
availability in the US is restricted because of these safety concerns.
Side effects are also associated with nasal and buccal forms of testosterone. Less
than 9% of Natesto users experience side effects which are usually associated with the
nasopharynx, such as nasopharyngitis. Striant is the bucally administered testosterone
that is most commonly associated with gingivitis. Over 32% of patients taking Striant
report gingivitis as a side effect.
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There are also side effects with transdermal testosterone medications. Androderm
has the highest occurrence of side effects with 57% of patients reporting skin irritation,
37% reporting pruritis, and 12-18% reporting a burn-like blister at the application site.
The greatest concern regarding the testosterone transdermal gel in pumps, packets, or
tubes is unintentional transdermal transfer to children or women. Androgel 1.62%
manufacturer data show that average testosterone levels in female partners increased by
280% after contact with the application site. However, when the application site was
covered by a shirt, average testosterone levels in female partners increased by only 613%. Testim is the only transdermal testosterone that showed no change in female partner
testosterone levels after covering the application site with a shirt.
Implications for Nurse Practitioners
	
  
NPs are in a great position to recognize and treat the effects of hypogonadism
with TRT. Hypogonadism is a problem that can be easily diagnosed and treated,
improving the lives of many men who suffer with the symptoms of testosterone
deficiency. When properly titrated, TRT medications return patients to normal
testosterone levels increasing energy, the ability to concentrate, bone density, and libido,
while lessening depression.
Selecting the best medication for TRT differs between patients and depends on
delicate balance of efficacy, compliance, cost, and potential side effects. The most
effective TRT medications are the transdermal preparations. The TRT medication with
the best patient compliance would be the injectable formulations. The most cost-efficient
TRT medications are Depotestosterone and Delatestryl, although there is a shortage of
Deletestryl and, as a result, it may be difficult to obtain. While the injectable Aveed could
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also improve patient compliance, it is not recommended at this time because of the
prohibitive cost and potential for serious side effects. Lastly, all TRT medications have
side effects. Although specific reports of Depotestosterone side effects may be lacking in
the literature, it has a good track record for being safe. Therefore, in consideration of
compliance, cost, and side effects of TRT medications, we recommend Depotestosterone
injection as a first line therapy option. Because it is injected once every 2-weeks,
Depotestosterone may not control testosterone levels as tightly as the transdermal
testosterone that is administered every day. For patients who are sensitive to the
testosterone peaks and troughs of Depotestosterone, we recommend altering the
administration schedule to a half dose every week rather than a full dose every 2-weeks.
Conclusion
Better understanding of the diagnosis, treatment, and management of
hypogonadism through continued research and best practice studies can improve the lives
of the aging male population. There are different TRT treatment options that should be
selected with careful consideration of efficacy, compliance, cost, and side effects. All
methods of testosterone delivery improve testosterone levels in patients. The NP should
select the appropriate TRT medication only when the patient is symptomatic and only
after conducting a thorough medical history and confirming low testosterone with a
serum testosterone level collected in the morning. In consideration of TRT medication
efficacy, patient compliance, medication cost, and common medication side effects, we
recommend the NP initiate treatment with Depotestosterone and then regularly follow up
with the patient to reevaluate efficacy, compliance, cost, and side effects.
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Table 1
Types of Testosterone Medications
Trade Name

Generic

Route

Available Dosing

Common Dose

Common
Frequency

Average Cost/Month
(calculated from common
dose)

Injectable
Depotestosterone

testosterone
cypionate

IM

100 mg/ml
200 mg/ml

200 mg/ml1

Q 2 weeks

100mg/ml (10ml vial) = $22.701
200mg/ml (10ml vial) = $18.451
200mg/ml (1ml vial) = $98.071

IM

200 mg/ml

200 mg/ml2

Q 2 weeks

200mg/ml (5ml vial) = $23.462

Aveed

testosterone
enanthate
N/A

IM

750 mg/3ml

750 mg/3ml2

Q 10
weeks

750mg/3ml (3ml vial)=
$379.603

Nasal
Natesto

N/A

Nasal gel

5.5 mg each
actuation

11 mg (1 actuation per
nostril) 2

TID

3 bottles (30 days) = $699.212

Buccal

30 mg

30 mg1

BID

60 tablets = $724.771

Patch

2 mg
4 mg

4 mg3

QD

30 patches = $195.031

Gel pump

1%-12.5mg/1.25g

50mg (4 pumps) 1

QD

2 bottles 1% (30 days) $309.242

1.62%-20.25mg/1.25g

40.5mg (2 pumps) 1

Gel pump
Gel pump
Gel pump

30mg /1.5ml
10mg/0.5g
12.5 mg/1.25g

60 mg (2 pumps) 1
40mg (4 pumps) 1
50mg (4 pumps)2

QD
QD
QD

1 bottle 1.62% (30 days)
$510.772
1 bottle (30 days) $630.78 1
1 bottle (30 days) = $281.802
2 bottles (30 days) = $283.692

Gel packet

1%-25mg/2.5g
1%-50mg/5g

50mg (1 packet) 1

QD

30 packets 1% = $309.252

1.62%-20.25mg/1.25g

40.5mg (1 packet) 1

Delatestryl

Buccal
Striant
N/A
Transdermal Patch
Androderm
N/A
Transdermal Gel Pump
AndroGel
testosterone 1%
1% or
1.62%

testosterone
1.62%
Axiron 2%
N/A
Fortesta 2% testosterone 2%
Vogelxo 1%
testosterone 1%
Transdermal Gel Packets
AndroGel
testosterone1%
1% or
1.62%

testosterone

25

30 packets 1.62% = $516.412

Vogelxo 1%

testosterone 1%

Gel packet

1%-25mg/2.5g
1%-50mg/5g

Testim 1%

testosterone 1%

Gel tube

50mg/5g

Vogelxo 1%

testosterone 1%

Gel tube

50mg/5g

50mg (1 packet) 1

QD

30 packets 1% = $270.302

Transdermal Gel Tubes
50mg2

QD

30 tubes = $268.252

50mg1

QD

30 tubes = $268.252

1

Epocrates
GoodRx.com
3
Drugs.com
2
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